RU2002103597A - COMPOSITION FOR TREATING VIOLATIONS OF EXTERNAL SECRETION - Google Patents
COMPOSITION FOR TREATING VIOLATIONS OF EXTERNAL SECRETIONInfo
- Publication number
- RU2002103597A RU2002103597A RU2002103597/15A RU2002103597A RU2002103597A RU 2002103597 A RU2002103597 A RU 2002103597A RU 2002103597/15 A RU2002103597/15 A RU 2002103597/15A RU 2002103597 A RU2002103597 A RU 2002103597A RU 2002103597 A RU2002103597 A RU 2002103597A
- Authority
- RU
- Russia
- Prior art keywords
- hydroxy
- alkyl
- halogen
- heterocyclic
- cyclo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 230000028327 secretion Effects 0.000 title claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 36
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004043 oxo group Chemical group O=* 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 10
- 230000002997 prostaglandinlike Effects 0.000 claims 9
- 125000004104 aryloxy group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010013781 Dry mouth Diseases 0.000 claims 2
- 229940012356 Eye Drops Drugs 0.000 claims 2
- 210000000214 Mouth Anatomy 0.000 claims 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims 2
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- -1 hydroxy- Chemical class 0.000 claims 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 239000006190 sub-lingual tablet Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
Claims (30)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14362799P | 1999-07-14 | 1999-07-14 | |
US60/143,627 | 1999-07-14 | ||
US60/143627 | 1999-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2002103597A true RU2002103597A (en) | 2003-11-10 |
RU2264816C2 RU2264816C2 (en) | 2005-11-27 |
Family
ID=22504885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002103597/15A RU2264816C2 (en) | 1999-07-14 | 2000-07-13 | Composition for treating disorders of external secretion |
Country Status (25)
Country | Link |
---|---|
US (3) | US6566398B1 (en) |
EP (1) | EP1223925B1 (en) |
JP (2) | JP4167828B2 (en) |
KR (1) | KR100750553B1 (en) |
CN (4) | CN100548977C (en) |
AR (2) | AR029381A1 (en) |
AT (1) | ATE344027T1 (en) |
AU (1) | AU779936B2 (en) |
BR (1) | BRPI0012387B1 (en) |
CA (1) | CA2377661C (en) |
CZ (1) | CZ303958B6 (en) |
DE (1) | DE60031710T2 (en) |
DK (1) | DK1223925T3 (en) |
ES (1) | ES2273706T3 (en) |
HK (1) | HK1048443B (en) |
HU (1) | HU229318B1 (en) |
IL (2) | IL147440A0 (en) |
MX (1) | MXPA02000437A (en) |
NO (1) | NO323908B1 (en) |
PT (1) | PT1223925E (en) |
RU (1) | RU2264816C2 (en) |
TR (1) | TR200200065T2 (en) |
TW (1) | TWI225398B (en) |
WO (1) | WO2001005388A2 (en) |
ZA (1) | ZA200109726B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI263505B (en) * | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
US20030232858A1 (en) * | 2002-06-14 | 2003-12-18 | Barker Ronnie C. | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
FR2850571B1 (en) * | 2003-01-31 | 2006-07-07 | Oreal | USE OF A JASMONIC ACID (DIHYDRO) DERIVATIVE FOR THE TREATMENT OF DRY SKINS |
US20040185075A1 (en) | 2003-01-31 | 2004-09-23 | Maria Dalko | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
JP4249185B2 (en) | 2003-10-06 | 2009-04-02 | 株式会社オフテクス | Ophthalmic composition for the treatment of tear abnormalities |
US7923471B2 (en) | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
WO2006007510A1 (en) * | 2004-07-01 | 2006-01-19 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
RU2440338C2 (en) * | 2005-01-27 | 2012-01-20 | Сукампо Аг | Method and composition for treatment of central nervous system disorders |
JP5213448B2 (en) * | 2005-03-04 | 2013-06-19 | スキャンポ・アーゲー | Methods and compositions for the treatment of peripheral vascular disease |
US7638142B2 (en) * | 2005-10-12 | 2009-12-29 | Vitamin Science, Inc. | Therapeutic composition for the treatment of dry eye syndrome |
KR20140147142A (en) | 2006-01-24 | 2014-12-29 | 가부시키가이샤 아루떼꾸 우에노 | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
EP2114411A2 (en) * | 2007-02-27 | 2009-11-11 | Sucampo AG | Composition and method for protecting mitochondria |
US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
US9161909B2 (en) | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
US9884082B2 (en) | 2008-11-13 | 2018-02-06 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
US9597278B2 (en) | 2008-11-13 | 2017-03-21 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
CN103313754B (en) | 2010-11-16 | 2015-09-30 | 小利兰·斯坦福大学理事会 | Be used for the treatment of the system and method for xerophthalmia |
US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
CN107903173A (en) * | 2011-08-05 | 2018-04-13 | 苏坎波公司 | Treat schizoid method |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
US10155108B2 (en) | 2013-04-19 | 2018-12-18 | Oculeve, Inc. | Nasal stimulation devices and methods |
EP3721938A1 (en) | 2014-10-22 | 2020-10-14 | Oculeve, Inc. | Stimulation devices and methods for treating dry eye |
EP3452166A4 (en) | 2016-05-02 | 2019-12-18 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
KR20210003716A (en) | 2018-04-26 | 2021-01-12 | 라이온 가부시키가이샤 | Exocrine promoter |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE49783B1 (en) | 1979-05-18 | 1985-12-11 | Efamol Ltd | Pharmaceutical and dietary composition comprising epsilon-linolenic acids |
GB8319073D0 (en) * | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
JPH0688966B2 (en) * | 1987-01-28 | 1994-11-09 | 株式会社アールテック・ウエノ | Prostaglandin Es and antiulcer drug containing the same |
JPH07103096B2 (en) * | 1987-01-28 | 1995-11-08 | 株式会社上野製薬応用研究所 | Prostaglandin Ds and sedative / sleeping agents containing the same |
DE3711164A1 (en) | 1987-04-02 | 1988-10-20 | Zeiss Carl Fa | PLUG-ELEMENT DEVICE FOR HOLDING COMPONENTS IN STACKS |
CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
JPS63277604A (en) | 1987-05-11 | 1988-11-15 | Showa Denko Kk | Alpha-linolenic acid-containing cosmetic |
JPH0692305B2 (en) * | 1987-05-15 | 1994-11-16 | 株式会社上野製薬応用研究所 | Body temperature increasing agent |
EP0455264B1 (en) * | 1987-09-18 | 1994-07-13 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
JP2579193B2 (en) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16-difluoro-15-oxo-15-deoxy PGE derivative |
AU4216089A (en) | 1988-08-12 | 1990-03-05 | Joel E. Bernstein | Method and composition for treating and preventing dry skin disorders |
CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
TW224942B (en) | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
JPH07100655B2 (en) * | 1990-04-04 | 1995-11-01 | 株式会社アールテック・ウエノ | Cataract treatment agent |
CA2041417C (en) * | 1990-05-01 | 2002-05-21 | Ryuji Ueno | Treatment of pancreatic disease with 15-keto-prostaglandin compounds |
JPH07113012B2 (en) * | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | Novel 15-keto-prostaglandins |
ATE141794T1 (en) * | 1991-03-14 | 1996-09-15 | R Tech Ueno Ltd | STIMULATING WOUND HEALING WITH 15-KETO PROSTAGLANDIN COMPOUNDS |
US5369127A (en) * | 1993-04-21 | 1994-11-29 | Allergan, Inc. | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents |
JP3183615B2 (en) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | Agent for treating liver and biliary diseases |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
TW420611B (en) * | 1995-03-10 | 2001-02-01 | R Tech Ueno Ltd | Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder |
US5696166A (en) * | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
WO2000038690A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of dry eye |
WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
RU2440338C2 (en) * | 2005-01-27 | 2012-01-20 | Сукампо Аг | Method and composition for treatment of central nervous system disorders |
JP5213448B2 (en) * | 2005-03-04 | 2013-06-19 | スキャンポ・アーゲー | Methods and compositions for the treatment of peripheral vascular disease |
-
2000
- 2000-07-12 TW TW089113876A patent/TWI225398B/en not_active IP Right Cessation
- 2000-07-13 AU AU58533/00A patent/AU779936B2/en not_active Ceased
- 2000-07-13 HU HU0202400A patent/HU229318B1/en not_active IP Right Cessation
- 2000-07-13 RU RU2002103597/15A patent/RU2264816C2/en not_active IP Right Cessation
- 2000-07-13 CN CNB2006101215152A patent/CN100548977C/en not_active Expired - Fee Related
- 2000-07-13 DK DK00944426T patent/DK1223925T3/en active
- 2000-07-13 KR KR1020027000471A patent/KR100750553B1/en active IP Right Grant
- 2000-07-13 AT AT00944426T patent/ATE344027T1/en active
- 2000-07-13 WO PCT/JP2000/004696 patent/WO2001005388A2/en not_active Application Discontinuation
- 2000-07-13 CA CA2377661A patent/CA2377661C/en not_active Expired - Lifetime
- 2000-07-13 US US09/615,703 patent/US6566398B1/en not_active Expired - Lifetime
- 2000-07-13 CN CN00810238A patent/CN1399548A/en active Pending
- 2000-07-13 CN CN200910205219A patent/CN101695495A/en active Pending
- 2000-07-13 CN CN2010101574518A patent/CN101829120B/en not_active Expired - Fee Related
- 2000-07-13 ES ES00944426T patent/ES2273706T3/en not_active Expired - Lifetime
- 2000-07-13 IL IL14744000A patent/IL147440A0/en unknown
- 2000-07-13 TR TR2002/00065T patent/TR200200065T2/en unknown
- 2000-07-13 DE DE60031710T patent/DE60031710T2/en not_active Expired - Lifetime
- 2000-07-13 MX MXPA02000437A patent/MXPA02000437A/en active IP Right Grant
- 2000-07-13 EP EP00944426A patent/EP1223925B1/en not_active Expired - Lifetime
- 2000-07-13 CZ CZ20020133A patent/CZ303958B6/en not_active IP Right Cessation
- 2000-07-13 BR BRPI0012387A patent/BRPI0012387B1/en not_active IP Right Cessation
- 2000-07-13 JP JP2001510445A patent/JP4167828B2/en not_active Expired - Fee Related
- 2000-07-13 PT PT00944426T patent/PT1223925E/en unknown
- 2000-07-14 AR ARP000103635A patent/AR029381A1/en not_active Application Discontinuation
-
2001
- 2001-11-27 ZA ZA200109726A patent/ZA200109726B/en unknown
-
2002
- 2002-01-02 IL IL147440A patent/IL147440A/en active IP Right Grant
- 2002-01-11 NO NO20020133A patent/NO323908B1/en not_active IP Right Cessation
-
2003
- 2003-01-21 HK HK03100518.0A patent/HK1048443B/en not_active IP Right Cessation
- 2003-03-04 US US10/377,743 patent/US20030171438A1/en not_active Abandoned
-
2004
- 2004-11-23 US US10/994,364 patent/US7396946B2/en not_active Expired - Fee Related
-
2008
- 2008-06-24 JP JP2008164252A patent/JP5052423B2/en not_active Expired - Fee Related
-
2009
- 2009-12-03 AR ARP090104665A patent/AR074465A2/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002103597A (en) | COMPOSITION FOR TREATING VIOLATIONS OF EXTERNAL SECRETION | |
CA2377661A1 (en) | Use of fatty acid derivative for the treatment of external secretion disorders | |
EP0084865B1 (en) | Propylene glycol diester solutions of pge-type compounds | |
JP2003504397A5 (en) | ||
TWI302100B (en) | Composition for treating drug-induced constipation | |
IE52854B1 (en) | Acetal stabilized prostaglandin compositions | |
RU2003109622A (en) | LIABILITY COMPOSITION | |
RU2005117964A (en) | SUBSTITUTED 4-ALCOXIOXOZAZOLE DERIVATIVES AS PPAR AGONISTS | |
AU2002251554A1 (en) | Composition for Treating Drug-Induced Constipation | |
KR950000663A (en) | Triterpene Derivatives and Endothelin-Receptor Antagonists Containing the Same | |
JP5427029B2 (en) | Methods and compositions for promoting gastrointestinal bicarbonate secretion | |
KR900016098A (en) | Derivatives of Caffeic Acid and Pharmaceutical Compositions Containing the Same | |
RU2004111357A (en) | COMBINED AGENTS FOR TREATMENT OF GLAUCOMA | |
TWI284535B (en) | Apoptosis inhibitor | |
EP0307061B1 (en) | Anxiolytically active piperazine derivatives | |
EP0214221B1 (en) | Ethanolamine derivatives for administering to livestock | |
JP2003526660A5 (en) | ||
TWI286932B (en) | Pharmaceutical composition for eliminating or reducing potential iridic pigmentation | |
RU2488398C2 (en) | Pharmaceutical combination of opioid and prostaglandin compound | |
KR930012019A (en) | Pharmaceutical composition for treating urination disorder | |
KR960704913A (en) | Novel Urethane-Containing Aminosteroid Compounds (NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS) | |
KR880004810A (en) | Peptic Ulcer Treatment | |
JP2004538306A5 (en) | ||
KR900701797A (en) | α-adrenergic receptor antagonists | |
JP2010519177A (en) | Compositions and methods for protecting mitochondria |